Showing 3841-3850 of 10206 results for "".
DermWireTV: AAD VMX Highlights, Upneeq Launches for Ptosis
https://practicaldermatology.com/topics/practice-management/dermwiretv-aad-vmx-highlights-upneeq-launches-for-ptosis/19931/The American Academy of Dermatology's VMX format delivers updates on a range of hot topics in dermatology, including an update on the COVID-19 dermatology vaccine registry from Esther Freeman, MD and teledermatology from Jules Lipoff, MD. Upneeq, a newly launched oxymetazoline eyedrop from RVL pharmAK Treatment Pearls
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-treatment-pearls/19731/Joel Cohen, MD and George Martin, MD go in depth to discuss nuances of treating actinic keratosis in a wide ranging conversation covering the concept of painless PDT and how pretreatment may enhance penetration, an update on ingenol mebutate, and a potential role for combination calcipotriene and 5-Update on Topical Acne Therapy for Adult Women
https://practicaldermatology.com/topics/general-topics/update-on-topical-acne-therapy-for-adult-women/19166/Diane Berson, MD, FAAD discusses the approach to management of acne in the adult female patient, emphasizing the role of vehicle to affect the patient experience, promote adherence, and optimize outcomes. Bonus Material: Hormonal Therapy for Female Acne Bonus Material: Procedures for Adult Female AThe Future of Laser and Device-based Procedures
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-future-of-laser-and-device-based-procedures/19345/New technologies and economic pressures on clinicians ensure a promising future for aesthetic laser treatment, according to Dr. Eric Bernstein.Analysis Evaluates Risks of Cardiovascular Events Among Biologics for Psoriatic Diseases
https://practicaldermatology.com/series/dermwire-tv/analysis-evaluates-risks-of-cardiovascular-events-among-biologics-for-psoriatic-diseases/32412/In this week's DermwireTV, a new analysis evaluates the risks of major adverse cardiovascular events among patients treated with biologics for psoriatic diseases; a phase 3 clinical trial examines the use of nemolizumab in adults with prurigo nodularis; and the president of Journey Medical discussesDilution Evolution
https://practicaldermatology.com/conferences/asds-2021/dilution-evolution/20025/Offering a global perspective on aesthetics, Hassan Galadari, MD discusses the use of hyperdilute calcium hydroxyapatite in the lower face, neck, and decolette. He describes the potential for this treatment to come to the US.Mastering Injection Techniques
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/mastering-injection-techniques/19736/Joel L. Cohen, MD reviews the takeaway messages from his lecture on injection techniques and use of fillers in body areas outside the face.Portfolio Management
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/portfolio-management/19702/Develop and use a portfolio of options to treat facial aesthetic concerns, urges Joel L. Cohen, MD as he talks about injectables, devices, and topicals for use in the cosmetic practice today.The Evolution of Injectables
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/anderson-2--apolesod/19038/Dina Anderson, MD, FAAD, discusses the changing landscape of injectable agents and how patients are more informed about various products and procedures.FDA Approves New Melanoma Treatment with Novel MOA
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dwtv-9-11-14--iloojede/19075/Merck's Keytruda, a novel PD-1 inhibitor, is approved for advanced melanoma, and a topical mole remover is being recalled.